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Background—Rocky Mountain spotted fever (RMSF) has emerged as a significant cause of 
morbidity and mortality since 2002 on tribal lands in Arizona. The explosive nature of this 
outbreak and the recognition of an unexpected tick vector, Rhipicephalus sanguineus, prompted an 
investigation to characterize RMSF in this unique setting and compare RMSF cases to similar 
illnesses.
Methods—We compared medical records of 205 patients with RMSF and 175 with non-RMSF 
illnesses that prompted RMSF testing during 2002–2011 from 2 Indian reservations in Arizona.
Results—RMSF cases in Arizona occurred year-round and peaked later (July–September) than 
RMSF cases reported from other US regions. Cases were younger (median age, 11 years) and 
reported fever and rash less frequently, compared to cases from other US regions. Fever was 
present in 81% of cases but not significantly different from that in patients with non-RMSF 
illnesses. Classic laboratory abnormalities such as low sodium and platelet counts had small and 
subtle differences between cases and patients with non-RMSF illnesses. Imaging studies reflected 
the variability and complexity of the illness but proved unhelpful in clarifying the early diagnosis.
Conclusions—RMSF epidemiology in this region appears different than RMSF elsewhere in the 
United States. No specific pattern of signs, symptoms, or laboratory findings occurred with 
enough frequency to consistently differentiate RMSF from other illnesses. Due to the nonspecific 
and variable nature of RMSF presentations, clinicians in this region should aggressively treat 
febrile illnesses and sepsis with doxycycline for suspected RMSF.
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Rocky Mountain spotted fever (RMSF), caused by the tick-borne pathogen Rickettsia 
rickettsii, was sporadically reported in Arizona prior to confirmation of a fatal case on an 
American Indian reservation in 2003, linked to an unexpected vector, Rhipicephalus 
sanguineus (the brown dog tick) [1, 2]. Through 2011, 219 human RMSF cases and 16 
fatalities (case fatality rate, 7.3%) were reported from 4 Arizona reservations, and 2 
additional reservations reported RMSF exposure in humans and/or dogs during 2012 [3, 4]. 
Affected tribes reported R. sanguineus infestation and large populations of free-roaming 
dogs [1, 2]. During the last decade, RMSF outbreaks caused by R. sanguineus have been 
documented in Mexico and South America [5, 6]. However, R. sanguineus ticks and the R. 
rickettsii organism found in Arizona are genetically distinct from those in Mexico, and the 
origin of the Arizona outbreak and reasons for its recent emergence remain unclear [5, 7, 8].
RMSF is easily treated with tetracyclines early in the illness, but other broad-spectrum 
antibiotics are not effective and doxycycline is the treatment of choice in patients of all ages 
[9–11]. The nonspecific clinical presentation of RMSF, lack of a sensitive early diagnostic 
test, and necessity of choosing an antibiotic not typically used for other common illnesses or 
sepsis make identification and management of cases challenging. Physicians need key 
information to guide early clinical decisions. Geographic patterns of infection and 
epidemiologic risk factors are important variables in these decisions.
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The Arizona RMSF outbreak is unusual because it occurred in association with a previously 
unrecognized tick vector in the United States, and emerged rapidly in a region where RMSF 
was not previously recognized. Its recent detection in tribal communities where multiple 
documented underlying health disparities exist [12, 13] lends importance and urgency to 
characterizing the epidemiology of this outbreak. The unique combination of host, vector, 
pathogen, and environmental variables within this outbreak suggest that important 
differences in the clinical manifestations and RMSF epidemiology may exist compared to 
the broader US experience [9, 14–17]. This study describes RMSF in this emerging setting 
to aid in differentiation of this potentially deadly disease from similar illnesses.
METHODS
Data, Definitions, and Analysis
We performed a retrospective medical record review of patients prompting R. rickettsii 
testing from 1 June 2002 through 30 September 2011 in community A, and 1 January 2005 
through 30 September 2011 in community B at community Indian Health Service health 
facilities and 11 referral hospitals. At least 1 illness symptom prompted RMSF testing; 
individuals tested without symptoms following a tick bite or exposures were excluded. This 
broad definition was intended to capture a complete spectrum of illness in patients tested for 
RMSF, considering that RMSF illnesses may be atypical or nonspecific.
A confirmed RMSF case was defined as a person reporting illness and a 4-fold change in 
immunoglobulin G (IgG)– or immunoglobulin M (IgM)–specific antibody titer reactive with 
R. rickettsii antigen by indirect immunofluorescence assay (IFA) between paired serum 
specimens taken after the onset of symptoms with at least 1 titer of ≥1:128 dilution, or 
detection of R. rickettsii DNA in a clinical specimen via amplification of a specific target by 
polymerase chain reaction (PCR) assay, or demonstration of spotted fever group antigen in a 
biopsy or autopsy specimen by immunohistochemical staining.
A probable RMSF case was defined as a person reporting illness and who did not meet 
criteria for a confirmed case, and had serologic evidence of elevated IgG or IgM antibody 
reactive with R. rickettsii antigen by IFA with at least 1 titer of ≥1:128 dilution.
A non-RMSF illness was defined as a person reporting illness and had at least 2 negative 
serologic R. rickettsii antigen titers (<1:64) and the second titer drawn no earlier than day 14 
after symptom onset.
All patients who met 1 of these definitions were included in this review. A subset of case 
samples underwent sequencing and restriction fragment length polymorphism analysis 
targeting rickettsial DNA, to confirm R. rickettsii as the pathogen. The nucleic acid 
sequence of this outbreak strain was published previously [5, 7]. Patients with titers of 1:64 
that did not increase were excluded from the review, because this low-level reactivity was 
considered insufficient evidence to confidently confirm or rule out recent infection.
Demographic information, medical history, illness history, and clinical information were 
anonymously recorded. Symptoms or exposures were excluded from analysis if there was no 
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documentation of their presence or absence. Data were analyzed using EpiInfo [18]. 
Statistical differences in categorical variables were evaluated using a χ2 test, and when the 
expected value of a cell was <5, Fisher exact test was used. Statistical differences in 
continuous variables were evaluated using an analysis of variance test or the Mann–
Whitney/Wilcoxon 2-sample test when a nonparametric test was more appropriate. 
Statistical significance was set at α = .05.
Health Facilities and Service Populations
Community A and B health facilities are, respectively, rural 40-bed and 8-bed Indian Health 
Service hospital and outpatient facilities on tribal reservations in Arizona, with user 
populations of >16 100 and >11 900 persons. Neither facility has an intensive care unit, 
resulting in patient transfers for specialized care to referral facilities.
Definitions of Terms
A case is a confirmed or probable RMSF case; dog contact is any documentation of dog 
interaction, including dog ownership or feeding strays; fever is a temperature ≥38°C 
(100.4°F) or reported fever by the patient or caretaker. Tick exposure includes tick bites and 
ticks observed on pets or in frequented environments. Abnormal laboratory values are those 
outside standard range; liver tests were based on age-adjusted standards.
Ethics Review
The project was intended to prevent disease in response to an immediate public health threat 
and was therefore judged exempt by the Centers for Disease Control and Prevention’s 
institutional review board on a nonresearch basis. The study was approved by the 




We identified 205 patients with RMSF (cases) and 175 with non-RMSF illnesses (Table 1). 
Among all subjects, 52% were male and all were American Indians except 1 person who 
worked on tribal lands. The median age among cases was 11 years, significantly higher than 
that of patients with non-RMSF illnesses (median, 2 years; Figure 1). Among cases, 85 had 
confirmed RMSF and 120 had probable RMSF. Cases occurred in each month, with 
seasonal differences in different peak months in communities A and B (September and July, 
respectively; Figure 2).
Exposures and Historical Medical Conditions
Dog contact and tick exposure were significantly more frequent among cases than among 
patients with non-RMSF illnesses (86% vs 69% and 55% vs 41%, respectively; Table 1). 
Sick contacts and travel frequency differed significantly between cases and patients with 
non-RMSF illnesses, but tick exposure was infrequently reported in both. The only medical 
history significantly more frequent among RMSF cases than patients with non-RMSF 
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illnesses was asthma, occurring in 8% of cases. Alcoholism and diabetes among adults were 
the most common underlying health conditions among cases; the frequency did not differ 
significantly from non-RMSF illnesses (27% vs 23% and 22% vs 20%, respectively).
Medical Care and Treatment
Cases and patients with non-RMSF illnesses both presented to health facilities a median of 2 
times during illness (cases: range, 0–9 and mean = 1.87; non-RMSF illness: range, 0–7 and 
mean = 1.94). Both first presented for care on median day 2 (cases: range, 1–11; non-RMSF 
illness: range, 1–12). Cases were significantly more likely to be treated with doxycycline 
than were patients with non-RMSF illnesses (87% vs 78%, respectively; risk ratio [RR], 
1.69; 95% confidence interval [CI], 1.09–2.62), and children more often than adults (91% vs 
81%, respectively; RR, 2.14; 95% CI, 1.05–4.37).
Fifteen fatalities (7.3%) and 86 (42.0%) hospitalizations (including 29 ICU admissions 
[14.1%]) occurred among cases. There were no deaths and 29 (16.6%) hospitalizations (7 
ICU admissions [4.0%]) among patients with non-RMSF illnesses. Cases were significantly 
more likely to result in fatality (RR undefined; P = .0007), hospitalization (RR, 2.53; 95% 
CI, 1.75–3.66; P < .0001), and ICU admission (RR, 3.53; 95% CI, 1.59–7.87; P < .0001) 
compared with patients with non-RMSF illnesses.
Signs and Symptoms
Fever was frequent but not universal among cases (81%; Table 2). Temperature maximum 
and range did not differ significantly between cases and patients with non-RMSF illnesses 
(38.8°C [range, 35.8°C–41.3°C] vs 38.4°C [range, 35.4°C–41.3°C]; Table 2). Although 
fever was present in all fatalities [11], no fever was documented in 8 of 85 (9%) confirmed 
cases (3 of whom were hospitalized) and 30 of 117 (26%) probable cases (4 of whom were 
hospitalized). Twenty cases without documented fever had a rash, and 14 reported a tick bite 
and other symptoms. One afebrile patient presented 5 days after symptom onset, required 
intensive care, suffered digit necrosis, and had a maximum temperature of 37.7°C. Patients 
without documented fever averaged 1.4 outpatient visits (range, 1–4). Rash occurred in 130 
of 192 (68%) cases and 92 of 166 (55%) non-RMSF illnesses. Twenty of 119 cases with 
rash descriptions reported pruritic rash (17%); another 4% were vesicular and 2% were 
urticarial, descriptions not usually associated with RMSF.
The triad of fever, rash, and tick exposure was significantly more frequent among cases than 
patients with non-RMSF illnesses (32% vs 16%, respectively; RR, 1.46; 95% CI, 1.16–
1.84), but represented a minority of cases.
Headache occurred in a majority of cases, but was not statistically more frequent than 
among patients with non-RMSF illnesses (58% vs 48%). Nausea (47%), red or draining eyes 
(15%), mental status change (17%), peripheral edema (12%), hepatomegaly (5%), and neck 
pain (11%) were all significantly more frequent among cases than patients with non-RMSF 
illnesses, but occurred in a minority of patients.
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The initial mean serum sodium level was significantly lower among cases than among 
patients with non-RMSF illnesses (Table 3), but only by 2 mEq/L (136 vs 138, 
respectively); chloride and potassium were similar (101 vs 103 and 3.9 vs 4.2, respectively). 
Initial platelet count mean was significantly lower among cases than among patients with 
non-RMSF illnesses, although not abnormally low for either group (269 × 103 platelets/µL 
vs 350 × 103 platelets/µL, respectively). However, initial platelet counts were low (<130 × 
103 platelets/µL) in 17 of 141 (12%) cases, compared to only 2 of 144 (1.4%) among 
patients with non-RMSF illnesses. White blood cell counts were similar, but neutrophil 
count was significantly higher (67% vs 56%) and lymphocyte and monocyte counts 
significantly lower (20% vs 32% and 7% vs 8%, respectively) among cases vs patients with 
non-RMSF illnesses.
Initial liver test means were often elevated among both adults and children, but only alanine 
aminotransferase and aspartate aminotransferase among adult cases were significantly 
higher among cases than among patients with non-RMSF illnesses. Among children, no 
liver tests were significantly more elevated among cases than among patients with non-
RMSF illnesses. Tests evaluating inflammatory and coagulation status (C-reactive protein, 
D-dimer, prothrombin time, partial thromboplastin time, international normalized ratio 
[INR], fibrinogen levels) were infrequently performed and usually conducted late in the 
illness course. When performed, prothrombin time, INR, and D-dimer differed significantly 
between cases and patients with non-RMSF illnesses.
Imaging Studies
Eighty-five (41.5%) confirmed or probable cases underwent at least 1 chest radiograph. Of 
these, 50 (59%) were interpreted as abnormal, and 19 (22%) specifically suggested 
pneumonia as a diagnosis. Head computed tomography (CT) scans were performed in 28 
(13.6%) patients, and 9 chest (4.4%), 11 abdominal (5.4%), and 4 pelvic CTs (2.0%) were 
documented. Magnetic resonance imaging studies were performed in 6 cases (5 head and 1 
extremity image). Ultrasound studies were performed in 21 (10.2%) cases including 17 
abdominal, 4 chest or cardiac, and 2 extremity studies. Nine of 17 (52.9%) abdominal 
ultrasounds were abnormal, including abnormal gallbladders, pericholecystic fluid, gallstone 
pancreatitis, cholelithiasis, hepatosplenomegaly, and hepatic steatosis.
Non-RMSF Illnesses
Non-RMSF illnesses were not always ascribed to a specific pathogen, as is true for many 
nonspecific febrile illnesses that are diagnosed and treated routinely in primary care settings. 
In this cohort, illness cause was occasionally confirmed as another bacteria or virus through 
diagnostic testing (bacterial cultures, rapid viral tests).
DISCUSSION
This review characterizes RMSF clinical characteristics and epidemiology since its 2002 
emergence in Arizona American Indian communities. In this series, RMSF disease patterns 
differed from US aggregate reports [19]. Although RMSF in most US regions peaks in June 
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and July, consistent with seasonal activity of Dermacentor variabilis and Dermacentor 
andersoni ticks, in Arizona human cases peaked in July and September in community B and 
community A, respectively (Figure 2). Both communities exhibited a bimodal pattern of 
disease onset, with declines during June, the driest month in both communities. Aggregate 
cases peaked during July–October (54.6%), corresponding with seasonal monsoons and 
indicating that climatic factors such as moisture may contribute to the ecology of tick 
populations and RMSF transmission in this region. Seasonal analysis also indicates that 
human RMSF infection exists year-round.
Although fever was frequent among both cases and patients with non-RMSF illnesses (81% 
and 84%, respectively), it was not universally detected in all RMSF cases, and fever among 
cases was less frequent than reported in other studies, ranging from 94% to 100% [20–26]. 
While this finding contrasts with much of the reported literature, it should be noted that 
presence of fever is a required symptom for national RMSF reporting [27], likely resulting 
in an inclusion bias for fever frequency among US reported cases and also likely causing 
physicians to discount RMSF consideration for patients without fever. Thirty-eight cases 
(19%) in our series lacked documented fever during the course of illness, including 8 of 85 
(9.4%) confirmed cases and 30 of 117 (25.6%) probable cases, suggesting that non-febrile 
RMSF illness occurs in this patient population, or that fever may not always be detected at 
the time a patient presents for care. For example, patients with sepsis or multiorgan system 
failure may exhibit hypothermia rather than fever, as occurred in late-presenting patients in 
this review. Probable cases only require 1 titer ≥1:128, allowing that an elevated titer may 
represent prior undetected RMSF illness with persistently elevated titer. However, a 
serosurvey conducted among children in the same communities during 2003–2004 revealed 
that only 10 of 215 (4.7%) children had R. rickettsii titers ≥1:128 [8]. The non-febrile 
probable cases, therefore, represent an RMSF infection that was either atypical because no 
fever was present or reported during patient evaluation, or a prior RMSF illness that was 
likely atypical or mild as it did not get tested for RMSF or come to medical attention at that 
time. Therefore, lack of fever should not exclude suspicion of RMSF in highly endemic 
areas such as this.
Strikingly, almost 50% of the cases in this review occurred in patients aged ≤10 years. The 
mean and median age among these cases (19.8 and 11 years, respectively) is lower than 
those of RMSF among the general US population (46 and 42 years, respectively) [28] and is 
lower than the mean age of 33 years reported among American Indians nationwide [29]. The 
younger age observed among these cases may reflect the unique vector and environmental 
factors in this region. The dog plays a central role in the RMSF transmission cycle in 
Arizona by harboring infected ticks [3, 8, 30]. Children may interact with dogs and their 
habitats more frequently than adults, resulting in greater exposure. In this series, the median 
age of those with non-RMSF illnesses was significantly lower than that of cases (2 vs 11 
years, respectively), likely because fever was considered an important indicator for RMSF 
testing, and fever occurs commonly in young children.
The variability of symptom frequency in this population makes a presumptive diagnosis of 
RMSF difficult for the clinician. Fever, present in 81% of patients and 100% of fatalities, 
was the most reliable indicator to guide timely, effective, and optimal treatment, although 
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fever was a late symptom in some fatalities [11]. No other signs or symptoms, either alone 
or in combination, were frequent enough to consistently identify at least two-thirds of RMSF 
cases. Rash was significantly more frequent among cases than among patients non-RMSF 
illnesses (68% vs 55%) but less common than that reported in numerous other studies [19–
22, 24–26]. Although rash is often considered a hallmark of RMSF, 60% of RMSF cases in 
this review lacked a demonstrable rash initially and 32% failed to develop any rash while ill. 
Fever and rash together occurred in significantly more cases (57%) than in patients with 
non-RMSF illnesses (41%), but this combination is too infrequent to exclude RMSF from 
consideration if both are not present. Cough, nasal congestion, ear pain, and irritability 
occurred significantly more frequently among patients with non-RMSF illnesses than cases, 
but could not be used reliably to rule out RMSF as they also often occurred in cases. This 
series also demonstrates that presence or absence of abnormal laboratory values is not 
reliable for early treatment decisions, since in many cases values were only slightly 
abnormal or did not turn abnormal until disease was advanced.
In this study, imaging procedures reflect widespread vasculitis and organ involvement that 
accompanies most RMSF cases. Abnormal findings indicating nonspecific inflammation 
may unfortunately lead the clinician away from an underlying diagnosis of RMSF. Because 
22% of chest radiographs in this series suggested pneumonia and 59% were abnormal, 
RMSF should be viewed as a potential etiology of community-acquired pneumonia (CAP) 
in this region. National guidelines for CAP treatment include doxycycline alone or paired 
with a β-lactam antibiotic [31], and clinicians should consider using doxycycline as part of 
standard treatment for CAP in patients from Arizona Indian reservations.
This review is subject to several limitations. Patients with titers <1:128 or with enzyme-
linked immunosorbent assay testing alone are included in the national case definition for 
reporting, but were excluded from this analysis to minimize false positives due to cross-
reactivity from non-rickettsial antigens. Because RMSF serology cross-reacts with other 
species of Rickettsia (including Rickettsia massiliae, which was detected in at least 1 tick 
from the region and has been reported to cause human illness in international settings [32, 
33]), patients diagnosed by serology alone could in theory be infected with other spotted 
fever group rickettsiae; however, R. massiliae patients typically have eschars [33, 34], which 
were lacking among these patients. Furthermore, PCR and nucleic acid testing of human 
specimens demonstrate R. rickettsii as the only detectable circulating Rickettsia species 
causing patient illness in this region.
In conclusion, this review characterizes RMSF during the first decade of emergence on 
tribal lands in Arizona. We found significant differences in the clinical presentation and 
epidemiology of disease compared to other parts of the United States, highlighting the need 
for region-specific medical education in this area. Providers in this region must remain 
vigilant for RMSF year-round and among younger ages than previously reported. The 
central role the dog plays in human exposure to rickettsial-containing R. sanguineus ticks 
emphasizes the importance of community-wide animal control and pet health programs, 
including tick prevention. The lack of a timely diagnostic RMSF test and the high fatality 
rate that occurs when RMSF treatment is delayed advocates that doxycycline be used 
aggressively among patients in this region presenting with a febrile illness and/or sepsis. 
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Additional analysis investigating the high fatality rate in this population is published 
elsewhere [11].
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Table 1
Demographics, Exposures, and Past Medical History Among Rocky Mountain Spotted Fever (RMSF) Cases 
and Patients With Non-RMSF Illness From 2 Tribal Communities in Arizona
Demographic Cases, No. (%) Non-RMSF Illness, No. (%) Risk Ratio 95% CI
No. of patients 205 175
Age, y, median/mean (range)* 11/19.8 (7 mo–78 y) 2/11.0 (2 mo–79 y) P = .000
Race 204 American Indian, 1 white 175 American Indian NA NA
Male sex 106/205 (52) 92/174 (53) 0.97 .80–1.18
Exposures
  Dog contact* 77/90 (86) 60/87 (69) 1.73 1.08–2.77
  Tick exposure* 73/132 (55) 48/118 (41) 1.32 1.04–1.67
  Sick contacts* 17/43 (40) 8/39 (21) 1.50 1.01–2.20
  Travel* 6/37 (16) 1/35 (3) 1.80 1.21–2.67
Past medical history
  Alcoholism (age >17 y) 22/81 (27) 8/35 (23) 1.07 .83–1.38
  Asthma* 17/205 (8) 2/174 (1) 1.71 1.43–2.06
  Autoimmune disorder 2/205 (1) 3/174 (2) 0.74 .25–2.16
  Diabetes (age >17 y) 18/82 (22) 7/35 (20) 1.04 .78–1.37
  Heart disease 4/205 (13) 3/174 (2) 1.05 .55–2.02
  Hepatitis 3/204 (2) 3/173 (2) 0.92 .41–2.10
  Hypertension 26/205 (13) 13/174 (8) 1.27 .99–1.62
  Lung disease, chronic 4/205 (2) 5/174 (3) 0.82 .39–1.71
  Renal insufficiency/failure 0/204 (0) 3/174 (2) 0 0–1.65
  Thyroid disease 6/205 (3) 4/174 (2) 1.11 .66–1.86
  Tuberculosis 2/204 (1) 2/174 (1) 0.93 .35–2.48
The following conditions were not present in any subjects included in this study: AIDS/human immunodeficiency virus, transplant recipients, 
asplenia, glucose-6-phosphate dehydrogenase deficiency.
The following conditions were present in 1 case and 1 patient with non-RMSF illness: cancer, cerebrovascular accident/stroke, deep vein 
thrombosis, and sickle cell disease.
Abbreviations: CI, confidence interval; NA, not applicable; RMSF, Rocky Mountain spotted fever.
*
Statistically significant difference.
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Table 2
Symptoms Among Rocky Mountain Spotted Fever (RMSF) Cases and Non-RMSF Illnesses From 2 Tribal 
Communities in Arizona
Symptom Cases, No. (%) Non-RMSF Illness, No. (%) Risk Ratio 95% CI
General and skin
  Fever 164/202 (81) 142/169 (84) 0.92 .73–1.15
  Tmax, median (range) 38.2°C (35.8–41.3) 38.3°C (35.4–41.3) P = .896
  Rash* 130/192 (68) 92/166 (55) 1.28 1.04–1.59
  Fever and rash* 108/190 (57) 71/164 (43) 1.29 1.06–1.57
  Fever and tick exposure 58/131 (44) 40/117 (34) 1.22 .96–1.53
  Rash and tick exposure* 48/128 (38) 23/114 (20) 1.44 1.15–1.81
  Triad (fever/rash/tick exposure)* 41/127 (32) 18/113 (16) 1.46 1.16–1.84
  Headache 78/135 (58) 37/77 (48) 1.15 .94–1.42
  Fatigue 60/130 (46) 23/65 (35) 1.16 .95–1.41
  Myalgia 53/129 (41) 28/61 (46) 0.94 .77–1.15
  Chills 47/133 (35) 24/69 (35) 1.01 .82–1.24
  Lethargy 24/121 (20) 12/57 (21) 0.98 .75–1.26
  Irritability 20/123 (16) 38/87 (44)* 0.51 .35–.74
  Lymphadenopathy 5/129 (4) 7/92 (8) 0.70 .36–1.38
Head/eyes/ears/nose/throat
  Nasal congestion* 43/155 (28) 66/136 (49) 0.64 .49–.83
  Sore throat 27/134 (20) 12/76 (16) 1.11 .87–1.41
  Red or draining eyes* 22/148 (15) 9/111 (8) 1.28 1.01–1.65
  Ear pain 13/126 (10) 15/69 (22) 0.69 .45–1.04
  Periorbital edema 7/147 (5) 3/105 (3) 1.21 .80–1.84
Pulmonary/cardiovascular
  Cough* 68/169 (40) 73/138 (53) 0.79 .64–.98
  Peripheral edema* 18/147 (12) 3/120 (3) 1.63 1.32–2.02
  Chest pain 12/129 (9) 4/65 (6) 1.17 .86–1.58
  Wheezing 9/164 (6) 14/147 (10) 0.73 .43–1.22
Gastrointestinal
  Nausea* 74/156 (47) 38/109 (35) 1.23 1.01–1.50
  Emesis 77/169 (46) 58/144 (40) 1.10 .90–1.35
  Anorexia 51/125 (41) 51/106 (48) 0.87 .68–1.11
  Diarrhea 52/163 (32) 45/137 (33) 0.98 .78–1.23
  Abdominal pain 48/154 (31) 25/115 (22) 1.22 .99–1.50
  Hepatomegaly* 7/145 (5) 1/124 (1) 1.65 1.24–2.20
  Jaundice 6/149 (4) 3/113 (3) 1.18 .73–1.90
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Symptom Cases, No. (%) Non-RMSF Illness, No. (%) Risk Ratio 95% CI
  Dysphagia 3/120 (3) 1/51 (2) 1.07 .60–1.90
  Splenomegaly 2/143 (1) 4/125 (3) 0.62 .20–1.93
Neurologic
  Dizziness 21/110 (19) 5/48 (10) 1.20 .96–1.50
  Mental status change* 29/169 (17) 5/137 (4) 1.66 1.38–1.99
  Neck pain* 16/141 (11) 2/74 (3) 1.40 1.15–1.70
  Seizure 7/142 (5) 3/78 (4) 1.09 .72–1.65
  Photophobia 5/117 (4) 1/45 (2) 1.16 .80–1.68
Abbreviations: CI, confidence interval; RMSF, Rocky Mountain spotted fever; Tmax, maximum documented temperature.
*
Statistically significant difference.
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